Stuart Therapeutics Announces Completion of Phase 3 Dry Eye Disease Clinical Trial
Stuart Therapeutics, Inc. (Stuart), a clinical-stage drug platform company developing novel therapies for ophthalmic diseases, today announced last patient last visit in the phase III study of its lead therapeutic candidate ST-100 (vezocolmitide) for treatment of Dry Eye Disease.Topline data results are expected in February 2025. https://mma.prnewswire.com/media/2602905/StuartTherapeutics_Florida.jpg “We are pleased to announce the completion of […]